By the way, AHA released the Late Breaking Clinical Trial schedule this morning for the November meeting. REDUCE-IT, CIRT and DECLARE-TIMI 58 for Vascepa, methotrexate and Farxiga, respectively, are all on the schedule. These should be the full trial data presentations for these three trials to follow up on the earlier top line announcements yesterday for REDUCE-IT and DECLARE-TIMI 58, and the CIRT trial halt announcement earlier this year.

On a side note, yesterday's REDUCE-IT top line announcement included an RRR number (25%). I previously stated that based on other recent CVOT top line announcements that I wasn't expecting an RRR number in the BETonMACE top line announcement. So perhaps it is not out of the realm of possibilities that BETonMACE top line Q1 2019 announcement will also contain a teaser RRR% prior to full data presentations later in 2019.